Search | Clinical Trials Finder

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 15
States / cities: Beverly Hills, California • Garden Grove, California • National City, California + 11 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Lisdexamfetamine Dimesylate 40 MG, Placebo; Drug
Lead sponsor: Gregory Fabiano; Other
Eligibility: 16 Years to 25 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: ADHD, Autism, Bipolar I Disorder, Conduct Disorder, Oppositional Defiant Disorder
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more

Conditions: Attention-Deficit Hyperactivity Disorder
Interventions: HLD200 (methylphenidate hydrochloride); Drug
Lead sponsor: Ironshore Pharmaceuticals and Development, Inc; Other
Eligibility: 6 Years to 17 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions: Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Artificial Intelligence-Assisted Supervision Protocol; Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 11 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
Interventions: QbMobile; Device
Lead sponsor: Qbtech AB; Industry
Eligibility: 6 Years to 60 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: San Jose, California • Largo, Florida • Orlando, Florida

Conditions: ADHD, Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine and OROS Methylphenidate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Onychophagia
Interventions: N-Acetylcysteine (NAC), Placebo; Drug · Other
Lead sponsor: Kevin Gray, MD; Other
Eligibility: 18 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: ADHD, Attention
Interventions: Cognitive training, Cognitive training-placebo; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 7 Years to 14 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Sacramento, California

Conditions: ADHD
Interventions: KP415 oral capsule, Placebo oral capsule; Drug
Lead sponsor: Zevra Therapeutics; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: TAK-137, TAK-137 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Marlton, New York

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: PF-03654746, Placebo capsules; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Lafayette, California • Los Alamitos, California • Newport Beach, California + 4 more

Conditions: ADHD, Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders
Interventions: OST Intervention for participants with Organizational skill difficulties; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 8 Years to 11 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Behavior, Child, Disruptive Behavior, Executive Dysfunction, Attention-deficit, Anxiety, Depression, Stress
Interventions: Treatment App, Sham app; Behavioral
Lead sponsor: New York University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: ADHD
Interventions: galantamine HBr; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 58 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: ADHD
Interventions: Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 42
States / cities: Encino, California • Garden Grove, California • Newport Beach, California + 37 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: EMS 7500 Digital Muscle Stimulator; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 7 Years to 14 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD), Attention Deficit Hyperactivity Disorder (ADHD), Schizophrenia Spectrum &Amp; Other Psychotic Disorders, Post Traumatic Stress Disorder, Obsessive Compulsive Disorder (OCD)
Interventions: Solicue Machine Learning Models, Mercuria Machine Learning Models; Diagnostic Test
Lead sponsor: Psyrin Inc.; Industry
Eligibility: 13 Years to 60 Years
Enrollment: 500 participants
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Brookline, Massachusetts • Zanesville, Ohio

Conditions: Depression, Anxiety, Disruptive Behavior Disorder, Trauma, Psychological
Interventions: Enhanced version of Interconnected Systems Framework, Positive Behavioral Interventions and Supports with Co-located School Mental Health; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: Not listed
Enrollment: 1,208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Greenville, North Carolina • Columbia, South Carolina

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: EmpowerPlus Lightning Sticks; Dietary Supplement
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 7 Years to 16 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Fetal Alcohol Spectrum Disorders, Attention Deficit Hyperactivity Disorder
Interventions: Trigeminal Nerve Stimulation (TNS); Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 8 Years to 12 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Attention Deficit Hyperactivity Disorder, ADHD
Interventions: Methylphenidate Hydrochloride Extended Release Capsule, Placebo; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Irvine, California

Conditions: Attention Deficit Hyperactivity Disorder Symptoms
Interventions: Behavioral/organizational skills intervention augmented with digital health application; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 11 Years to 15 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Investigating the Effect of Vortioxetine in Adult ADHD Patients

Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

Community-Based Care for Minority Adolescents With ADHD: Improving Fidelity With Machine Learning-Assisted Supervision and Fidelity Feedback.

An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

Use of N-Acetylcysteine (NAC) in Fingernail Biting

Effects of Cognitive Training on Academic Task Performance in Attention Deficit Hyperactivity Disorder (ADHD)

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase

Randomized Controlled Trial of a Behavioral Training App

A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)

Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models

Improving Social, Emotional, Behavioral, and Academic Functioning

Feasibility and Acceptability of Powdered Multinutrient Formula

Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

Development of a Mobile App for an Executive Functioning Intervention for Adolescents